Market news
Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx’s commercial gene therapy portfolio and manufacturing footprint in the U.S. We’ll now explore how FAYUVI’s first-in-disease approval and the associated...
Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
Wall Street raised Ultragenyx’s price target after the U.S. Food and Drug Administration approved Fayuvi to treat children with Sanfilippo syndrome Type A.
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultrage
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.
Ultragenyx Pharmaceuticals won approval for its newest gene therapy on Thursday, helping shares partially reverse a dive.
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A Ultragenyx’s UltraCare® program will support access, and commercial product is expected to be available to ship to Qualified Treatment Centers within 30-60 days FAYUVI marks the second gene therapy approval, and sixth FDA approval overall, for Ultragenyx The Company received a Priority R
FDA approves Ultragenyx’s Fayuvi, first pediatric gene therapy for Sanfilippo A targeting root cause. Read more here.
RARE investors are now awaiting an FDA decision on UX111, the company’s one-time gene therapy for Sanfilippo syndrome type A.
Ultragenyx Pharmaceutical stock is under pressure after a multi year slide in returns, yet current market multiples still screen as expensive and the broader valuation checks send a mixed message. With fresh clinical setbacks alongside some positive data elsewhere in the pipeline, investors face conflicting signals about what the current price really reflects. Over the past 5 years the share price has fallen about 85%, which points to a sharp reset in market expectations for Ultragenyx...
Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.
The company's experimental Angelman syndrome treatment failed.
Ultragenyx shares plunged after its Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet key endpoints. Click for an analysis on RARE.
Here are some of the companies making headlines in midday trading.
Ultragenyx (RARE) stock plunges as analysts downgrade the company after a late-stage trial setback for its treatment for Angelman syndrome. Read more here.
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
Following the late-stage miss, analysts raise concerns around potential readthrough to another ongoing study in Angelman syndrome involving apazunersen.
Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls
This is the newest page. Registered accounts read further back.